Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.37, $0.08 better than the analyst estimate of $3.29. Revenue for the quarter came in at $2.07 billion versus the consensus estimate of $2 billion.

GUIDANCE:

Vertex Pharma sees FY2022 revenue of $8.4-8.6 billion, versus the consensus of $8.22 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.